Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention

Journal of Interventional Cardiology

Volumn 18, Issue 1, 2005, Pages 33-37

  Razakjr, Omar Abdul ^a   Tan, Huay Cheem ^a   Yip, Wei Luen ^a   Lim, Yean Teng ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CORONARY ARTERY DISEASE; FEMALE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STROKE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA;

EID: 16344393739     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2005.04031.x     Document Type: Article

References (23)

1. Heras M, Chesebro JH, Penny WJ, et al. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988;78:654-660.
2. Scharf RE, Tomer A, Marzec UM, et al. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb 1992;12:1475-1487.
3. Tschoepe D, Schultheiss HP, Kolarov P, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993;88:37-42.
4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
5. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: Impact II. Lancet 1997;349:1422-1428.
6. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-1435. Erratum in Lancet 1997;350:744.
7. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-1435. Erratum in Lancet 1997;350:744.
8. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
9. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary ansioplasty. Circulation 1997;96:1445-1453.
10. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
11. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
12. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000;356:2037-2044. Erratum in: Lancet 2001;357:1370.
13. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000;356:2037-2044. Erratum in: Lancet 2001;357:1370.
14. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1993;22:2033-2054.
15. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991;115:256-265.
16. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-1764.
17. Philips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80(Suppl 4A):11B-20B.
18. Tan HC, Lim YT, Lim TT, et al. The use of Abciximab in coronary angioplasty-an Asian centre's experience. Singapore Med J 2000;41:69-73.
19. Lincoff AM, Tcheng JE, Bass TA, et al. A multicentre, randomised, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-2890.
20. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-2890.
21. Blankenship JC. Bleeding complications of glycoprotein IIb/IIIa receptor inhibitors. Am Heart J 1999;138:287-296.
22. Fuchs S, Komowski R, Mehran R, et al. Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty. J Invasive Cardiol 2000;12:497-501.
23. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813.